• Genmab average return on tangible equity for 2023 was 15.1, a 30.41% increase from 2022.
• Genmab average return on tangible equity for 2022 was 21.7, a 47.32% decline from 2021.
• Genmab average return on tangible equity for 2021 was 14.73, a 55.62% increase from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.